CLYM Key Statistics, Chart & Performance
The current stock price of CLYM is 5.14 USD. In the past month the price increased by 16.22%. In the past year, price increased by 171.58%.
CLYM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CLYM. When comparing the yearly performance of all stocks, CLYM is one of the better performing stocks in the market, outperforming 98.38% of all stocks.
CLYM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLYM. While CLYM has a great health rating, there are worries on its profitability.
CLYM Financial Highlights
Over the last trailing twelve months CLYM reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 64.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.84% | ||
| ROE | -28.67% | ||
| Debt/Equity | 0 |
CLYM Forecast & Estimates
13 analysts have analysed CLYM and the average price target is 9.69 USD. This implies a price increase of 88.52% is expected in the next year compared to the current price of 5.14.
CLYM Ownership
About CLYM
Company Profile
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Company Info
CLIMB BIO INC
20 William Street, Suite 145
Wellesley Hills MASSACHUSETTS US
Employees: 17
Phone: 18668572596
CLIMB BIO INC / CLYM FAQ
What does CLYM do?
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Can you provide the latest stock price for CLIMB BIO INC?
The current stock price of CLYM is 5.14 USD. The price decreased by -0.39% in the last trading session.
Does CLIMB BIO INC pay dividends?
CLYM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLYM stock?
CLYM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is CLIMB BIO INC (CLYM) stock traded?
CLYM stock is listed on the Nasdaq exchange.